Hormonal · Dosing reference

Gonadorelin dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Approved, no longer marketedBLimited human dataLabel not retrievable

Full research page Cycle-length evidence Compare Prefer Amiravo on Google

Regulatory status: Approved, no longer marketed
Human amounts: Approved product discontinued; no current label text retrievable
Route studied: —
Frequency: —
Half-life: A review describes native GnRH as having low potency and a short half-life, which is why longer-acting analogues were developed; it gives no numerical value, and no half-life figure for gonadorelin was verified for this entry ^1.
Evidence grade: Grade B · Limited human data
Vial sizes on the market: Not recorded
Other forms seen: —

What Gonadorelin is

Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH), studied in research on the hypothalamic-pituitary-gonadal axis.

Gonadorelin is identical to native gonadotropin-releasing hormone. Released from the hypothalamus into the portal circulation, it acts on pituitary gonadotrophs to regulate production and release of luteinizing hormone and follicle-stimulating hormone, which in turn drive gonadal function ^1. Receptor The human GnRH receptor is a rhodopsin-like, class A G-protein coupled receptor that is unusual in lacking a… How it works →

Key evidence

Pace et al., American Family Physician · 1991 · Review of human endocrinology and therapeutics
Describes gonadorelin as synthetic GnRH, its first use as a diagnostic test of pituitary luteinizing hormone and follicle-stimulating hormone reserve, its later therapeutic use in hypogonadal and infertility states, and the development of long-acting analogues that instead suppress gonadotropin secretion. ¹
Christou, Pitteloud and Gomez, Gynecological Endocrinology · 2017 · Humans (12 women with amenorrhoea of hypothalamic origin seeking pregnancy)
Ovulation was documented in all patients after a mean of 17 days of pump stimulation, with single ovulation in 30 of 33 cycles regardless of route and ten pregnancies across seven patients; a comparison patient with polycystic ovary syndrome showed a premature luteinizing hormone surge without ovulation. ⁹
Gronier et al., Gynecologie Obstetrique & Fertilite (in French) · 2014 · Humans (review of pulsatile GnRH practice in hypogonadotropic hypogonadism)
Reports cumulative pregnancy rates estimated between 70% and 100% after six cycles of pulsatile GnRH, with an average of 2.8 cycles to pregnancy and low rates of complications and multiple pregnancy, while describing the method as underused. ¹⁰

All studies on the research page

What the human evidence shows

Approved product, discontinued; no retrievable label

We searched PubMed and ClinicalTrials.gov and found no human studies that administered Gonadorelin. The research described on its page is from cells or animals, and animal amounts do not translate to people.

How long did human studies run?

No human study durations are recorded for Gonadorelin.

Cycle-length evidence for Gonadorelin

Side effects reported in studies

Premature luteinizing hormone surge without ovulation
Reported in the single comparison patient with polycystic ovary syndrome in a 12-patient series · Woman with polycystic ovary syndrome treated with pulsatile GnRH in the same protocol as women with hypothalamic amenorrhoea ⁹
Multiple pregnancy and complications of ovulation induction
Described as low with pulsatile GnRH relative to other ovulation induction methods; not quantified as a rate in the source · Women with hypogonadotropic hypogonadism treated by GnRH pump ¹⁰
Pituitary apoplexy following combined provocative pituitary testing
Single reported case; frequency not established · Patient with acromegaly due to a giant pituitary adenoma undergoing combined TRH and GnRH stimulation testing ¹¹

Full adverse-event data

Gonadorelin draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength

2 · Water added

3 · Amount per draw

4 · Syringe

Your mix

10 mg + 2 mL water = 5 mg/mL

10 units holds 0.5 mg (500 mcg)

Draw toEnter an amount in step 3

U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Water	mg/mL	Draw
0.5 mL	20	—
1 mL	10	—
1.5 mL	6.667	—
2 mL	5	—
2.5 mL	4	—
3 mL	3.333	—
5 mL	2	—

Supplies and handling

Lyophilized vial
Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
Sterile diluent
The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
Graduated syringes
Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
Alcohol prep pads
For wiping vial stoppers before each puncture.
Nitrile gloves
Clean gloves for aseptic handling.
Sharps container
Puncture-resistant container for used needles.

Step-by-step reconstitution guide Storage and transport accessories

Storage

General research-context handling only: the lyophilised peptide is normally kept cold, dry and protected from light, and is less stable in solution than as a dry powder. There is no current human finished product label to defer to, so handling guidance has to come from the supplier's own documentation and local institutional requirements; veterinary product labelling addresses animal use and is not a human handling reference ^2,3. Amiravo gives no preparation or handling instructions.

Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent: The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed: Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles: Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution: This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed: Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status: Gonadorelin acetate was approved in the United States under NDA 019687 (LUTREPULSE KIT, Ferring), but both products under that application are flagged Discontinued in Drugs@FDA, and the only gonadorelin labels currently in DailyMed are veterinary (Factrel, Cystorelin, Fertagyl, Gonabreed, Ovacyst). There is no current human product ^2,3.
United States (FDA): Gonadorelin acetate was approved in the United States under NDA 019687 (LUTREPULSE KIT, Ferring), but both products under that application are flagged Discontinued in Drugs@FDA, so there is no currently marketed approved human product ^2. The only gonadorelin labels currently in DailyMed are veterinary: Factrel (gonadorelin hydrochloride, Zoetis), Cystorelin (Boehringer Ingelheim Animal Health), Fertagyl (Merck Sharp & Dohme), Gonabreed (Parnell) and Ovacyst (Bimeda) ^3. A veterinary label is an approval for use in animals and says nothing about human use. Gonadorelin does not appear in any of the three categories of FDA's 503A bulk drug substances list as updated May 14, 2026 ^12.
Sport (WADA): Gonadorelin is named explicitly on the WADA 2026 Prohibited List. Section S2.2.1 lists "gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues" under the heading "Testosterone-stimulating peptides in males including, but not limited to:", within section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which is prohibited at all times, both in and out of competition ^4. The "including, but not limited to" wording means the list of named agents in that subsection is illustrative rather than exhaustive.

Status varies by country and changes over time. How we describe regulatory status.

Gonadorelin compared with related compounds

Compound	Status	Evidence	Human amounts	Half-life
Gonadorelin	Approved, no longer marketed	B	Label not retrievable	A review describes native GnRH as having
Leuprolide	FDA-approved	A	FDA label	Approximately 3 hours (elimination, two-
Kisspeptin-54	Not approved — research use only	B	None established	About 28 minutes (intravenous, healthy m
Triptorelin	FDA-approved	A	FDA label	Terminal half-life about 3 hours after I
Kisspeptin-10	Not approved — research use only	B	None established	—
NAD+	Not approved — research use only	B	None established	—

Frequently asked questions

What doses of Gonadorelin have been studied in humans?

Gonadorelin is investigational. This page lists the amounts given in each cited trial as facts about those studies.

Is there an established Gonadorelin cycle length?

No. We found no human studies that report treatment duration for Gonadorelin.

How much bacteriostatic water should be added to a Gonadorelin vial?

There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.

How many units is a given amount on an insulin syringe?

On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.

What is the half-life of Gonadorelin?

A review describes native GnRH as having low potency and a short half-life, which is why longer-acting analogues were developed; it gives no numerical value, and no half-life figure for gonadorelin was verified for this entry ^1.

Is Gonadorelin FDA-approved?

Approved, no longer marketed. Gonadorelin acetate was approved in the United States under NDA 019687 (LUTREPULSE KIT, Ferring), but both products under that application are flagged Discontinued in Drugs@FDA, and the only gonadorelin labels currently in DailyMed are veterinary (Factrel, Cystorelin, Fertagyl, Gonabreed, Ovacyst). There is no current human product ^2,3.

References

GnRH agonists: gonadorelin, leuprolide and nafarelin Am Fam Physician. 1991
Drugs@FDA application record for gonadorelin acetate: NDA 019687 (LUTREPULSE KIT, Ferring), products flagged Discontinued FDA Drugs@FDA / openFDA drug/drugsfda. 2026
DailyMed label search for gonadorelin, returning veterinary products only (Factrel, Cystorelin, Fertagyl, Gonabreed, Ovacyst) NLM DailyMed. 2026
World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026
Gonadotropin-Releasing Hormone (GnRH) Receptor Structure and GnRH Binding Front Endocrinol (Lausanne). 2017
Ovulation Induction Techniques StatPearls. 2023
History of Puberty: Normal and Precocious Horm Res Paediatr. 2022
Gonadotropin-releasing hormone stimulation test and diagnostic cutoff in precocious puberty: a mini review Ann Pediatr Endocrinol Metab. 2020
The induction of ovulation by pulsatile administration of GnRH: an appropriate method in hypothalamic amenorrhea Gynecol Endocrinol. 2017
[Ovulation induction by pulsatile GnRH therapy in 2014: literature review and synthesis of current practice] Gynecol Obstet Fertil. 2014
Pituitary apoplexy probably due to TRH and GnRH stimulation tests in a patient with acromegaly J Endocrinol Invest. 1999
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act, updated May 14, 2026 FDA. 2026

Last reviewed October 22, 2026 by the Amiravo editorial team. Editorial policy · Report an error